Who are Lispro Mid Mix's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tresiba, Levemir, Apidra, Lantus, Novolog, Humalog.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lispro-mid-mix.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lispro Mid Mix — Competitive Intelligence Brief

Lispro Mid Mix (Lispro Mid Mix) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin combination therapy. Area: Diabetes.

marketed Insulin combination therapy Insulin receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Lispro Mid Mix (Lispro Mid Mix) — Eli Lilly and Company. Lispro Mid Mix is a fixed-ratio combination of rapid-acting insulin lispro and intermediate-acting insulin isophane that mimics the body's natural insulin secretion pattern by providing both immediate and sustained glucose control.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lispro Mid Mix TARGET	Lispro Mid Mix	Eli Lilly and Company	marketed	Insulin combination therapy	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin combination therapy class)

Eli Lilly and Company · 3 drugs in this class
Hospital Universitario San Ignacio · 1 drug in this class
Peking University People's Hospital · 1 drug in this class
Riverside University Health System Medical Center · 1 drug in this class
Tehran University of Medical Sciences · 1 drug in this class
Université NAZI BONI · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lispro Mid Mix — Competitive Intelligence Brief. https://druglandscape.com/ci/lispro-mid-mix. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab